To determine useful immunohistochemical markers for tumor cells in extramammary Paget’s disease (EMPD), immunohistochemical (IHC) examinations in 17 patients with EMPD, including 4 patients with dermal invasion, were performed. Among the antibodies examined, cytokeratin 7 (CK7) and CK19 were strongly positive for both intraepidermal and dermally invasive tumor cells in all patients. CAM5.2 and mucin 1 (MUC1) were also good markers. Although IHC examination revealed positive for HER-2 in 4 EMPD patients with dermal invasion, 4 out of 13 noninvasive patients were IHC negative. Fluorescence in situ hybridization (FISH) study revealed negative results for HER-2 gene amplification in 8 IHC positive patients, including each 4 patients of both noninvasive and dermal invasive cases. Our results show that besides CK7, CK19 is another favorable marker of tumor cells of EMPD. Four patients with dermal invasion were strongly positive for HER-2, although negative results were obtained in the FISH study. Further investigations are required to confirm the results of the FISH study.
OrdonetzNGAwaltHMackayB. Mammary and extramammary Paget’s disease: an immunocytochemical and ultrastructural study. Cancer. 1987;59:1173-1183.
2.
GanjeiPGiraldoKALampeBNadjiM. Vulvar Paget’s disease. Is immunohistochemistry helpful in assessing the surgical margins?J Reprod Med. 1990;35:1002-1005.
3.
LieglBLeiblSGogg-KamererMTessaroBHornLCMoinfarF. Mammary and extramammary Paget’s disease: an immunohistochemical study of 83 cases. Histopathology. 2007;50:439-447.
4.
ThwayKPolsonAPopeRThomasJMFisherC. Extramammary Paget disease in a retrorectal dermoid cyst: report of a unique case. Am J Surg Pathol. 2008;32:635-639.
5.
YoshiiNYonezawaSMatsukitaSMatsukitaSSetoyamaMKanzakiT. Expression of mucin core proteins in extramammary Paget’s disease. Pathol Int. 2002;52:390-399.
6.
MoriOHachisukaHNakanoSSasaiYShikuH. Expression of ras p21 in mammary and extramammary Paget’s disease. Arch Pathol Lab Med. 1990;114:858-861.
7.
NakamuraGShikataNShojiTHatanoTHiokiKTsuburaA. Immunohistochemical study of mammary and extramammary Paget’s disease. Anticancer Res. 1995;15:467-470.
8.
YanaiHTakahashiNOmoriM. Immunohistochemistry of p63 in primary and secondary vulvar Paget’s disease. Pathol Int. 2008;58:648-651.
9.
ChenSMoroiYUrabeK. Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget’s disease. Clin Exp Dermatol. 2008;33:634-640.
10.
XieLNHayashideSKidoM. Stromal CD10 expression is correlated with invasiveness and proliferation of extramammary Paget disease. Br J Dermatol. 2008;158:1389-1391.
11.
AoyagiSAkiyamaMShimizuH. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget’s disease. J Dermatol Sci. 2008;50:177-184.
12.
EllisPEMacleanABCrowJCWongTeFongLFRolfeKJPerrettCW. Expression of cyclin D1 and retinoblastoma protein in Paget’s disease of the vulva and breast: an immunohistochemical study of 108 cases. Histopathology. 2009;55:709-715.
13.
ImamAYoshidaSOTaylorCR. Distinguishing tumour cells of mammary from extramammary Paget’s disease using antibodies to two different glycoproteins from human milk-fat-globule membrane. Br J Cancer. 1988;58:373-378.
14.
RegauerS. Extramammary Paget’s disease—a proliferation of adnexal origin?Histopathology. 2006;48:723-729.
15.
KeatingsLSinclairJWrightC. c-erbB-2 oncoprotein expression in mammary and extramammary Paget’s disease: an immunohistochemical study. Histopathology. 1990;17:243-247.
16.
NishiMYoshidaHSetoyamaMTashiroM. Immunohistochemical study of c-erbB-2 oncoprotein expression in extramammary Paget’s disease. Dermatology. 1994;188:100-102.
17.
TakataMFujimotoAAokiHHattaNOoiATakeharaK. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget’s disease. J Invest Dermatol. 1999;113:258-262.
18.
PlazaJATorres-CabalaCIvanDPrietoVG. HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutan Pathol. 2009;36:729-733.
19.
OgawaTNagashimaYWadaH. Extramammary Paget’s disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Hum Pathol. 2005;36:1273-1280.
20.
TanskanenMJahkolaTAsko-SeljavaaraSJalkanenJIsolaJ. HER2 oncogene amplification in extramammary Paget’s disease. Histopathology. 2003;42:575-579.
21.
OhtsukiYFujitaJHachisukaY. Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and interstitial pneumonia. Med Mol Morphol. 2007;40:198-202.
22.
OhtsukiYNakanishiNFujitaJ. Immunohistochemical distribution of SP-D, compared with those of SP-A and KL-6 in interstitial pneumonias. Med Mol Morphol. 2007;40:163-167.
23.
TsudaHAkiyamaFTerasakiH. Detection of HER-2/neu(c-erb B-2)DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
24.
DowsettMBartlettJEllisIO. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 32 centres. J Pathol. 2003;199:418-423.
25.
PressMFSauterGBernsteinL. Diagnostic elevation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
